Denise A Yardley

Summary

Affiliation: Sarah Cannon Cancer Center
Country: USA

Publications

  1. pmc Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, 250 25th Avenue N, Suite 100, Nashville, TN, 37203, USA
    Breast Cancer Res Treat 145:725-34. 2014
  2. pmc Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, Tennessee, USA
    Breast Cancer (Auckl) 7:7-22. 2013
  3. ncbi request reprint Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA
    Breast Cancer Res Treat 142:655-65. 2013
  4. pmc Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, 37203, USA
    Adv Ther 30:870-84. 2013
  5. doi request reprint nab-Paclitaxel mechanisms of action and delivery
    Denise A Yardley
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN 37203, USA
    J Control Release 170:365-72. 2013
  6. doi request reprint Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata
    Denise A Yardley
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 100, Nashville, TN 37203, USA
    J Clin Oncol 31:2128-35. 2013
  7. pmc Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN, USA
    Breast Cancer Res Treat 137:457-64. 2013
  8. doi request reprint Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A Yardley
    The Sarah Cannon Research Institute and Tennessee Oncology, Suite 110, 250 25th Ave North, Nashville, TN 37203, USA
    Breast Cancer Res Treat 136:759-67. 2012
  9. doi request reprint Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:178-83. 2009
  10. doi request reprint Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 10:64-73. 2010

Detail Information

Publications52

  1. pmc Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, 250 25th Avenue N, Suite 100, Nashville, TN, 37203, USA
    Breast Cancer Res Treat 145:725-34. 2014
    ..These differences may be due to effects of prior drug exposure and could have implications for designing and interpreting clinical trials...
  2. pmc Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, Tennessee, USA
    Breast Cancer (Auckl) 7:7-22. 2013
    ..Combination therapies targeting multiple components of these central signaling pathways may be an optimal treatment strategy for patients with advanced breast cancer...
  3. ncbi request reprint Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA
    Breast Cancer Res Treat 142:655-65. 2013
    ..Maintenance bevacizumab monotherapy did not identify any new safety signals. Breast cancer recurrence/relapse, secondary malignancies, and death were uncommon, although the follow-up time in this study was relatively short...
  4. pmc Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, 37203, USA
    Adv Ther 30:870-84. 2013
    ..Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population...
  5. doi request reprint nab-Paclitaxel mechanisms of action and delivery
    Denise A Yardley
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN 37203, USA
    J Control Release 170:365-72. 2013
    ..Continued preclinical and clinical research across a range of tumor types is warranted to answer the questions that remain on the mechanisms of delivery and antitumor activity of nab-paclitaxel...
  6. doi request reprint Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata
    Denise A Yardley
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 100, Nashville, TN 37203, USA
    J Clin Oncol 31:2128-35. 2013
    ..This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor exemestane versus exemestane alone...
  7. pmc Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN, USA
    Breast Cancer Res Treat 137:457-64. 2013
    ..1-64.6), respectively. Lapatinib 1,000 mg with nab-paclitaxel 100 mg/m(2) IV is feasible with manageable and predictable toxicity and an ORR of 53 % comparing favorably with other HER2-based combinations in this setting...
  8. doi request reprint Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A Yardley
    The Sarah Cannon Research Institute and Tennessee Oncology, Suite 110, 250 25th Ave North, Nashville, TN 37203, USA
    Breast Cancer Res Treat 136:759-67. 2012
    ..The trial did not meet its prespecified primary endpoint, and in view of the negative results obtained in several other trials, sunitinib will not be developed further for this indication...
  9. doi request reprint Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:178-83. 2009
    ..We investigated the activity and toxicity of the gemcitabine/trastuzumab combination as first- or second-line treatment in women with HER2+ metastatic breast cancer (MBC)...
  10. doi request reprint Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 10:64-73. 2010
    ..Responses to ixabepilone in patients with visceral metastases were comparable to those observed in overall study patient populations...
  11. doi request reprint Proactive management of adverse events maintains the clinical benefit of ixabepilone
    Denise A Yardley
    Breast Cancer Research, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    Oncologist 14:448-55. 2009
    ..By effectively managing adverse events and taking steps to minimize them, clinicians can ensure that patients derive the maximum benefit from ixabepilone therapy...
  12. ncbi request reprint Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 8:487-92. 2008
    ..The clinical results support the hypothesis that ixabepilone can overcome or circumvent primary mechanisms of resistance to taxanes and other chemotherapeutic agents...
  13. ncbi request reprint Integrating gemcitabine into breast cancer therapy
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Oncology (Williston Park) 18:37-48. 2004
    ..Gemcitabine now remains under active investigation for the treatment of early-stage breast cancer, with ongoing trials characterizing its role in the neoadjuvant setting...
  14. ncbi request reprint Gemcitabine and taxanes as a new standard of care in breast cancer
    Denise A Yardley
    Sarah Cannon Cancer Center, Tennessee Oncology, Nashville, TN 37203, USA
    Clin Breast Cancer 4:S107-12. 2004
    ..Either as a single agent or in combination with the taxanes, gemcitabine remains a rational choice for the treatment of breast cancer...
  15. doi request reprint Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety
    Denise A Yardley
    The Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 10:119-29. 2010
    ..This review analyzes the cardiac safety profile of bevacizumab in breast cancer, with a focus on early-stage disease, and the ongoing clinical development of this important new drug...
  16. ncbi request reprint Gemcitabine plus paclitaxel in breast cancer
    Denise A Yardley
    The Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, USA
    Semin Oncol 32:S14-21. 2005
    ....
  17. doi request reprint A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine
    Jeffrey R Infante
    Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA
    Cancer Chemother Pharmacol 69:137-44. 2012
    ..To address tolerability and a possible pharmacologic interaction of capecitabine with sorafenib...
  18. ncbi request reprint Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network
    F Anthony Greco
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA
    Clin Lung Cancer 8:483-7. 2007
    ....
  19. ncbi request reprint Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    J Thorac Oncol 2:854-61. 2007
    ..Imatinib targets KIT expression, providing rationale for studying its role in combination with chemotherapy in SCLC in a multicenter phase II trial...
  20. ncbi request reprint A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Adv Hematol Oncol 9:280-6. 2011
    ..To examine the safety of sorafenib combined with standard adjuvant treatment in patients with node-positive or otherwise high-risk breast cancer...
  21. doi request reprint Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:237-42. 2009
    ..The efficacy of weekly docetaxel is not improved by concurrent administration of imatinib as a PDGFR inhibitor...
  22. doi request reprint A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Breast Cancer 8:425-31. 2008
    ....
  23. doi request reprint A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 10:367-72. 2010
    ..Patients and..
  24. ncbi request reprint A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors
    Suzanne F Jones
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Adv Hematol Oncol 9:225-30. 2011
    ..To evaluate the safety and tolerability of the combination of orally administered panobinostat with gemcitabine in patients with advanced solid tumors...
  25. doi request reprint A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
    Suzanne F Jones
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer Chemother Pharmacol 70:471-5. 2012
    ..To determine the maximum tolerated doses and dose-limiting toxicities of oral panobinostat in combination with paclitaxel and carboplatin when administered to patients with advanced solid tumors...
  26. doi request reprint Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 11:297-305. 2011
    ..We investigated the feasibility and efficacy of bevacizumab in combination with trastuzumab, nab-paclitaxel, and carboplatin as neoadjuvant therapy for women with locally advanced HER2(+) breast cancer...
  27. doi request reprint Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer
    Howard A Burris
    Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN 37203, USA
    Cancer Invest 28:408-12. 2010
    ..These results do not support further investigation of thalidomide for MBC. The role of angiogenesis inhibition in breast cancer treatment should continue to be defined using more efficacious and specific inhibitors...
  28. doi request reprint Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer
    Jeffrey R Infante
    Tennessee Oncology, PLLC, Nashville, TN, USA
    Clin Breast Cancer 9:23-8. 2009
    ..We investigated the feasibility and safety of a 3-drug combination of trastuzumab, docetaxel, and vinorelbine as first-line therapy in this patient group...
  29. doi request reprint Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 4:1555-60. 2009
    ..Bevacizumab's role in the treatment of small cell lung cancer (SCLC) is unknown. A multicenter phase II trial with bevacizumab plus chemotherapy was conducted in patients with untreated extensive-stage SCLC...
  30. doi request reprint A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, Tennesee, USA
    Cancer Invest 28:925-31. 2010
    ..The vinflunine/trastuzumab combination was active and well tolerated, but our results do not suggest advantages over taxane/trastuzumab or vinorelbine/trastuzumab...
  31. ncbi request reprint Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Lung Cancer 7:127-32. 2005
    ..Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients...
  32. ncbi request reprint A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN, USA
    Clin Breast Cancer 10:217-23. 2010
    ..We explored the combination of gemcitabine/epirubicin/docetaxel as neoadjuvant therapy. Docetaxel was administered weekly to decrease myelosuppression...
  33. doi request reprint Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 11:146-52. 2011
    ..This phase II trial evaluated the feasibility and efficacy of bevacizumab added to either anastrozole or fulvestrant in the first-line treatment of patients who have hormone receptor-positive metastatic breast cancer...
  34. doi request reprint A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer Invest 28:865-71. 2010
    ..8 months). Substitution of oxaliplatin for cisplatin or carboplatin, in combination with trastuzumab, does not appear to improve first-/second-line therapy in HER2-positive MBC...
  35. ncbi request reprint Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial
    F Anthony Greco
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA
    Oncologist 9:644-52. 2004
    ....
  36. ncbi request reprint Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Cancer Invest 24:469-73. 2006
    ..Epirubicin, a doxorubicin analog, has shown modest toxicity advantages when compared to the parent compound. In this Phase II trial, we evaluated the activity and toxicity of a docetaxel/epirubicin combination...
  37. doi request reprint A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer
    Jeffrey R Infante
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Eur J Cancer 47:199-205. 2011
    ..This phase I study was performed to identify the optimal dose of pomalidomide to be used in combination with gemcitabine in the treatment of patients with metastatic pancreatic cancer...
  38. doi request reprint A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:247-52. 2009
    ..We aim to compare the efficacy and toxicity of liposomal doxorubicin and weekly docetaxel as first-line treatments for patients with metastatic breast cancer (MBC)...
  39. ncbi request reprint Phase I. Trial of irinotecan plus carboplatin in two dose schedules
    Suzanne F Jones
    Sarah Cannon Cancer Center, Tennessee Oncology, PLLC Nashville, Tennessee, USA
    Oncology (Williston Park) 17:36-40. 2003
    ..With this amended regimen, the recommended phase II doses are irinotecan at 90 mg/m2 in combination with carboplatin at AUC 2.0 on days 1 and 8, with treatment cycles repeated every 21 days...
  40. doi request reprint Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab
    David R Spigel
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 28:43-8. 2010
    ..Strategies to safely incorporate novel antiangiogenic agents into combined-modality therapy in lung cancer are needed...
  41. ncbi request reprint A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies
    Suzanne F Jones
    Drug Development Program, Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Clin Adv Hematol Oncol 9:845-52. 2011
    ..This phase I study was conducted to determine the dose-limiting toxicity, maximum-tolerated doses, and recommended phase II doses of the combination of vatalanib and bevacizumab...
  42. ncbi request reprint Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer Invest 120:408-12. 2010
    ..These results do not support further investigation of thalidomide for MBC. The role of angiogenesis inhibition in breast cancer treatment should continue to be defined using more efficacious and specific inhibitors...
  43. doi request reprint A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Breast Cancer 8:242-8. 2008
    ..Because docetaxel might be more active than paclitaxel in the treatment of metastatic breast cancer, we explored the feasibility of substituting docetaxel for paclitaxel in dose-dense adjuvant therapy...
  44. ncbi request reprint Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Nashville, TN, USA
    J Clin Oncol 20:4261-7. 2002
    ....
  45. ncbi request reprint Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Cancer J 8:311-21. 2002
    ..The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of a novel combined-modality treatment for patients with locally advanced squamous carcinoma of the head and neck...
  46. ncbi request reprint Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer
    Denise A Yardley
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Semin Oncol 31:37-44. 2004
    ..From its favorable therapeutic index to substantial efficacy in combination with docetaxel, gemcitabine remains a rational and important addition to the treatment armamentarium of breast cancer...
  47. pmc Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction
    F Anthony Greco
    Tennessee Oncology, PLLC, Nashville, Tennessee, USA
    Oncologist 15:500-6. 2010
    ..This retrospective, multi-institutional study evaluated the accuracy of tissue-of-origin prediction by molecular profiling in patients with carcinoma of unknown primary site (CUP)...
  48. doi request reprint Updates in the treatment of basal/triple-negative breast cancer
    Mythili Shastry
    Sarah Cannon Research Institute, Nashville, Tennessee, USA
    Curr Opin Obstet Gynecol 25:40-8. 2013
    ..This review summarizes recent progress and studies in TNBC and discusses some of the ongoing clinical trials and emerging therapies for the treatment of TNBC...
  49. ncbi request reprint Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:38-45. 2006
    ....
  50. ncbi request reprint Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer
    Joyce A O'Shaughnessy
    Texas Oncology, PA, USA
    Clin Breast Cancer 6:143-9. 2005
    ..This phase II study evaluated the efficacy, safety, and health outcomes of pemetrexed treatment in heavily pretreated patients with advanced breast cancer...
  51. ncbi request reprint Loss of FHIT expression in breast cancer is correlated with poor prognostic markers
    Banu Arun
    Division of Hematology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard 424, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 14:1681-5. 2005
    ....